Abbott Head of Medical Affairs, Brazil |
Major Activities: |
Humira Launch Preparation: building and development of a Medical Affairs team: 08 medical managers; 03 MM for each Humira indication and 02 MSLs for RA (before 2003, there were only 04 MM). |
Interaction with Peers: |
|
Achievements: |
|
Genzyme Head of Clinical Operations, Latin America |
Major Activities: |
Leadership of re-structuring of Genzyme’s Clinical Operations Area, building and developing a multicultural, multifunctional, multidisciplinary regional team: from 12 to 40 HCs, based in BR, ARG, CHI, COL and MEX. |
Interaction with Peers: |
|
Achievements: |
|
Vertex Head of Medical Affairs, Latin America |
Major Activities: |
First employee to join Vertex in Latin America, building the Medical Affairs organization: 04 MSLs, 01 project coordinator and 01 assistant. |
Interaction with Peers: |
|
Achievements: |
|
Abbott |
Project: |
Support to regulatory and reimbursement submission |
Product: |
Simdax (levosimendan) |
Description: |
The Brazilian Evaluation of Levosimendan Infusion Efficacy (BELIEF) study was prospective, multicenter, and observational and included 182 high-risk DHF patients and 10 HF Centers levosimendan. This HEOR data were collected as well. |
Interaction with Peers: |
|
Achievements: |
|
Abbott |
Project: |
Collaboration study with Marketing team in order to create awareness of primary hypothyroidism. |
Product: |
Synthroid (levothyroxine) |
Description: |
Epidemiology study conducted in Rio de Janeiro city: 1,500 households visited. |
Interaction with Peers: |
|
Achievements: |
|
Genzyme |
Project: |
Support to Pricing and Reimbursement dossiers, developed by a local. |
Product: |
Cerdelga (eliglusat) |
Description: |
Support to a local vendor in the adaptation and validation of Core Value Dossier. |
Interaction with Peers: |
|
Achievements: |
|
Vertex |
Project: |
Brazil CFTR Sequencing Project: |
Product: |
Kalydeco Orkambi Symdeco Trikafta |
Description: |
Mapping of 3,000 CF patients enrolled in the Brazilian CF Registry. As all CFTR modulators are mutation-specific, it is important to genotype all patients using Next Generation Sequencing (NGS). |
Interaction with Peers: |
|
Achievements: |
|
Vertex | |||
Product: |
Kalydeco (ivacaftor) | Orkambi (Luma/ivacaftor) |
Symdeco (teza/Ivacaftor) |
Description: |
Development of CMED and CONITEC dossier | Development of CMED and CONITEC dossier | Development of CMED dossier |
Interaction with Peers: |
|
||
Achievements: |
|
|
|